Academic to Start-up Experience
Kenneth R. Chien, MD, PhD
Karolinska Institutet / Wallenberg-Karolinska CardioVascular Initiative, Department of Cell and Molecular Biology and Medicine and Scientific Co-Founder of Moderna Therapeutics
Kenneth R. Chien, MD, PhD received a Presidential appointment as a Professor to Karolinska Institutet, in 2013. Professor Kenneth Chien was previously the Charles and Elizabeth Ann Sanders Professor in the Department of Stem Cell and Regenerative Biology at Harvard University. From 2005-2009, he was appointed as Scientific Director of the Cardiovascular Research Center at Massachusetts General Hospital in Boston.
Professor Chien graduated from Harvard College in 1973 and earned his MD in 1980 and PhD in 1983 from Temple University in Pennsylvania. After completing his internship, residency, and cardiology fellowship training at the University of Texas Southwestern Medical School in Dallas, he joined the faculty of the UCSD Departments of Medicine and Cardiology and the Center for Molecular Genetics. Subsequently, Dr. Chien became the Director of the UCSD Institute of Molecular Medicine and directed the joint UCSD-Salk Institute National Institutes of Health Molecular Medicine Training Program.
Dr. Chien is an internationally recognized leader in cardiovascular science, as well as a pioneer in developing new therapeutic strategies to prevent the onset and progression of heart failure. At Karolinska Institutet, Professor Chien leads a team of physicians and scientist on the pathways for human cardiogenesis, with a goal of finding new insights into congenital heart disease in children, as well as novel pathways and principles for regenerative medicine and the repair of damaged cardiac muscle cells.
He is a recipient of the Walter B. Cannon Award of the American Physiology Society, the Pasarow Foundation Award and a member of the Norwegian Academy of Sciences, the Austrian Academy of Sciences, and honorary doctorate of the University of Edinburgh for his work. Recently he was appointed as a Distinguished Professorship of the Swedish Research Council, and Director of the Karolinska-Wallenberg Cardiovascular Initiative.
Professor Chien also has served as a senior consultant and board member to several biotechnology and large pharmas over the past decade, fostering collaborative ties between academia and the private sector. Dr. Chien was also heavily involved in the establishment of the Institute of Molecular Medicine at Peking University, currently the premier site for cardiovascular science in China.
Allen C. Eaves MD, PhD, FRCPC
Founder, Owner and Chief Executive Officer, STEMCELL Technologies Inc
Dr. Allen Eaves, MD PhD FRCPC, has been Founding Director of the Terry Fox Laboratory (1981-2006), Head of Hematology at the University of British Columbia (1985-2003), President of the International Society of Cell Therapy (1995-1997), President of the American Society of Blood and Marrow Transplantation (1999-2000), and Founding Treasurer of the Foundation for the Accreditation of Cellular Therapies (1995-2002). As Professor Emeritus of Hematology (2006 – present), he is the founder, owner and CEO of STEMCELL Technologies, Canada’s largest biotech company, with over 600 employees and the major sponsor of ISSCR 2014 in Vancouver. A supporter of Canada’s Networks of Centres of Excellence, he sits on The Board of Mprime (successor of MITACS), The Canadian Stem Cell Network, The Centre for Commercialization of Regenerative Medicine, and The Canadian Foundation for Stem Cell Research.
Hans S. Keirstead, PhD
President, NeoStem Oncology
Hans S. Keirstead, PhD is President of NeoStem Oncology. Dr. Keirstead is an internationally known stem cell expert with extensive basic research and clinical experience. He has developed stem cell-based therapies for late stage cancers, motor neuron diseases, spinal cord injury and retinal diseases. Dr. Keirstead is President of NeoStem Oncology (NBS; NASDAQ). Prior to this appointment, NeoStem acquired California Stem Cell, Inc. (CSC), which Dr. Keirstead founded and served as President and CEO. Venture Capital perspective
Other management experience includes founder and CEO of Ability Biomedical Corporation, whose technology was sold to Bristol-Myers Squibb. He founded and directed the Sue and Bill Gross Stem Cell Research Center at the University of California at Irvine as a stem cell-dedicated Professor of that institute for 16 years, and served as a Scientific Advisory Committee Member of the initiative that resulted in the California Institute of Regenerative Medicine, a $3 billion stem cell fund. Dr. Keirstead received his Ph.D. in neuroscience from the University of British Columbia in Vancouver, Canada, for which he received the Cameron Award for the outstanding Ph.D. thesis in the country, and his Post-Doctoral Fellowship from Cambridge University, England, where he serves as a lifelong member of Downing College. He has over 100 scientific publications, and has formally influenced stem cell policy in several nations.
Robert Millman, JD
CEO and Co-Founder, Semma Therapeutics, USA
Robert Millman, JD serves as the Chief Executive Officer and Co-founder of Semma Therapeutics. Mr. Millman has helped form and served as the start-up IP Counsel of several MPM portfolio companies, including Epizyme, iPierian and Verastem. He has most recently founded and led CoStim Pharmaceuticals as its first President, a company focused on cancer immunotherapy. Mr. Millman has also served as an IP counsel for several important portfolio companies during funding, development or transactions, including Peplin, Syndax and Valeritas. Prior to joining MPM, he was Chief IP Counsel at Alnylam Pharmaceuticals Inc., the Chief IP Counsel at Infinity Pharmaceuticals, Inc., the Chief IP Counsel at Celera Genomics, and Patent Counsel at Millennium Pharmaceuticals, Inc. Earlier in his career, Mr. Millman was an associate at Morrison and Foerster LLP and a patent agent/specialist at Sterne, Kessler Goldstein and Fox, LLP. He received his J.D. degree from the Washington College of Law at The American University, an M.S. degree in Genetics from Washington State University and a B.S. degree in Biochemistry from the University of California, Riverside. Large pharma views on investing, partnering and innovation translation
Kenneth Drazan, MD Large Biotechnology to startup experience
Head, Johnson & Johnson Innovation, California
Thomas J. Livelli
Vice President, Life Sciences, Promega Corporation
Thomas J. Livelli is the Vice President of Life Sciences at Promega Corporation, bringing with him over 30 years of experience in Molecular Cell Biology. Tom is responsible for the Pharma/Biotech and the Academic/Government market segments at Promega, working with the business teams to drive the strategy for these markets. Tom manages the Cellular Analysis, Genomics and Proteomics business units, as well as the Strategic Collaboration Management Team and SciApps Lab. Panelist
Prior to joining Promega, Tom was Vice President, Cellular Assay Systems and Collaborations Management at Invitrogen/Life Technologies Discovery Sciences. Prior to Invitrogen/Life Technologies, Tom was the President & CEO of Cell & Molecular Technologies Inc. (CMT), a biotechnology company he founded in 1997 and took public in 1998. CMT was acquired by Invitrogen in December of 2006.
Tom did research in and managed the laboratory of Nobel Laureate Dr. Richard Axel at the Howard Hughes Medical Institute at Columbia University College of Physicians & Surgeons from 1986 to 1997. Tom’s research was focused on building cell-based assays to interrogate GPCR biology. Tom received his Bachelor of Arts degree in Biology from Columbia University in 1977.
Annika Espander, BSc, MBA
Chief Executive Officer and Founder, Asperia AB
Annika Espander, BSc, MBA is Chief Executive Officer and Founder of Asperia AB. Ms. Espander holds a BSc in Chemistry from the University of Michigan, Ann Arbor/University of Uppsala and holds an Executive MBA degree in International Business Management from the University of Uppsala, Sweden. She has also completed three years of academic research at the Medical Faculty, Department of Medicinal Chemistry and Physiology, University of Gothenburg, Sweden. Previously, she held various executive positions such as Global Head of Private Banking, Special Client Solutions and Foundation Services, Chair of the Board, Handelsbanken Luxembourg (2010-2013), Managing Partner at Catella Healthcare AB (2004-2008) with investments in public and private companies in different segments of the healthcare industry, and Global Head of Equity and Credit Research at Handelsbanken Capital Markets (2002-2004).
Before turning to investment banking, Ms. Espander worked at Pharmacia Peptide Hormones (1991 to 1994) as the Global Project Manager within clinical research of growth factors, primarily Growth Hormone and IGF-1. In the stem cell area, Ms Espander and her team at Catella Healthcare were the largest investors in Cellartis, an embryonic stem cell company. Currently, Ms. Espander is running a strategic and advisory business in the healthcare and financial services sectors. She is also a senior advisor to private equity funds in healthcare and other sectors as well as a strategic communication advisor. Ms. Espander runs a network of senior advisors with long term executive management experience, serves on the board of Symphogen and acts as a mentor and Senior Advisor in the Mentor for Research Program at the Royal Academy of Sciences in Sweden.